TrialBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy2022

A Clinical Prediction Model to Determine Probability of Response to Certolizumab Pegol for Crohn's Disease.

Pavine L C Lefevre et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.